EP Patent

EP1061946B1 — Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Assigned to Novo Nordisk AS · Expires 2004-04-28 · 22y expired

What this patent protects

The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative of improved solubility and/or stability, and to a method for improving the solubility and/or stability of GLP-1 or a fragment or an analogue thereof.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative of improved solubility and/or stability, and to a method for improving the solubility and/or stability of GLP-1 or a fragment or an analogue thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1061946B1
Jurisdiction
EP
Classification
—
Expires
2004-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.